PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK)-Reference-Cited by-同舟云学术

PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK)

Published:2022-11 Issue: Volume:175 Page:99-106
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Lorenzen Sylvie,Quante Michael,Rauscher Isabel,Slotta-Huspenina Julia,Weichert Wilko,Feith Marcus,Friess Helmut,Combs Stefanie E.,Weber Wolfgang A.,Haller Bernhard,Angele Martin,Albertsmeier Markus,Blankenstein Christiane,Kasper Stefan,Schmid Roland M.,Bassermann Florian,Schwaiger Markus,Liffers Sven-Thorsten,Siveke Jens T.

Funder

Deutschen Konsortium für Translationale Krebsforschung

School of Medicine

Technische Universität München

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

2. Preoperative chemoradiotherapy for esophageal or junctional cancer;van Hagen;N Engl J Med,2012

3. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial;Eyck;J Clin Oncol,2021